Ongoing Clinical Trials for High Grade B-Cell Lymphoma Burkitt-Like Lymphoma
There are currently 2 ongoing clinical trials exploring new treatment approaches for high grade B-cell lymphoma Burkitt-like lymphoma. These studies are testing innovative therapies including targeted medications and advanced cell-based treatments in patients whose disease has not responded to standard care or has returned after treatment.
Clinical trial locations
- Denmark
- Germany
- Greece
Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma
This trial is testing whether adding acalabrutinib to a standard chemotherapy combination can help patients live longer without their disease getting worse. The study focuses on older adults with previously untreated disease.
Who can participate: This study is designed for adults over 80 years old, or adults aged 60 to 80 who cannot tolerate full-dose standard chemotherapy. Participants must have confirmed CD20-positive disease with specific stages of advancement. They need to have adequate organ function, including acceptable blood counts, liver, and kidney function. Patients must be able to understand the study purpose, give informed consent, and take medications in capsule and tablet form without difficulty. Both men and women of childbearing potential must agree to use effective contraception during the study.
Who cannot participate: The trial excludes patients with types of cancer other than the specific forms listed in the study. Those who have already received treatment for their lymphoma, those younger than 60 who can tolerate full-dose chemotherapy, and those unable to take the study medications due to allergies are not eligible. Pregnant or breastfeeding women, patients with severe heart problems or uncontrolled medical conditions, those with active infections requiring treatment, and individuals participating in other clinical trials at the same time cannot join.
Study focus: The main goal is to determine if adding acalabrutinib to the R-miniCHOP regimen improves progression-free survival compared to R-miniCHOP alone. Participants will be randomly assigned to receive either the combination treatment or the standard therapy. The treatment is given in cycles over a specific period, with regular monitoring through physical examinations, blood tests, and imaging studies to evaluate response and manage any side effects.
Investigational drugs: The study uses acalabrutinib, a medication that blocks a protein called Bruton’s tyrosine kinase that helps cancer cells grow. It is combined with rituximab, which targets and helps destroy cancer cells, and R-miniCHOP, a reduced-dose chemotherapy combination that includes doxorubicin, cyclophosphamide, vincristine, and prednisone.
Study on CLIC-1901 CAR T-cells and Tocilizumab for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin Lymphoma
This trial is investigating an advanced form of treatment called CAR T-cell therapy for patients whose cancer has returned or has not responded to previous treatments. The therapy uses a patient’s own immune cells that are modified in a laboratory to better recognize and attack cancer cells.
Who can participate: Patients between 1 and 70 years old with blood cancers that have come back or not responded to treatment may be eligible. They must have a life expectancy of at least 12 weeks and adequate organ function, including a general health score above 50%, lung function at least 40% of expected performance with oxygen levels above 90%, heart function greater than 45%, and acceptable liver and kidney function. Participants must sign an informed consent form and agree to use very effective birth control methods from a specific procedure until at least 12 months after receiving treatment.
Who cannot participate: Patients with certain types of cancer who have not responded to previous treatments or whose cancer has returned might not be eligible depending on specific circumstances. Those outside the specified age range and individuals considered part of vulnerable populations requiring special protection are excluded from participation.
Study focus: The study aims to test the safety and feasibility of using CLIC-1901 CAR T-cell therapy in treating blood cancers that have not responded to other treatments. The process involves collecting white blood cells through a procedure called leukapheresis, modifying them in a laboratory over several weeks, and then infusing them back into the patient through an intravenous line. Close monitoring follows to observe the body’s response and manage any side effects, with regular follow-up visits to assess health status.
Investigational drugs: The study uses CLIC-1901 CAR T-cells, specially modified immune cells engineered to recognize and attack cancer cells that express a protein called CD19. The trial also involves tocilizumab (RoActemra), a medication given as an infusion to help manage potential side effects of the CAR T-cell therapy.
Summary
These two clinical trials represent different approaches to treating aggressive B-cell lymphomas. The first trial focuses on older adults with newly diagnosed disease who cannot tolerate intensive chemotherapy, testing whether adding a targeted medication to a reduced-intensity chemotherapy regimen can improve outcomes. This study is available in both Greece and Germany.
The second trial takes a different approach, using advanced cell-based immunotherapy for patients of various ages whose cancer has already returned or resisted previous treatments. This study is being conducted in Denmark and represents a more experimental treatment approach using the patient’s own modified immune cells.
Both studies reflect the ongoing effort to develop more effective and tailored treatment options for these challenging blood cancers, with one focusing on improving initial treatment for those who cannot tolerate standard therapy, and the other exploring innovative options for patients who have exhausted conventional treatments.
